Jonathan Kushi, MD
Rheumatology · Glendale, WINPI 1073692901
Payments from drug & device makers
Across 300 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$701
- Pfizer$689
- AstraZeneca$463
- UCB, Inc.$305
- GSK$300
- plus $2K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 62 | $1,173 |
| Amgen(2 entities) | 37 | $701 |
| Pfizer | 59 | $689 |
| AstraZeneca(2 entities) | 19 | $463 |
| UCB, Inc. | 16 | $305 |
| GSK | 21 | $300 |
| Johnson & Johnson | 14 | $289 |
| Genentech USA, Inc. | 10 | $204 |
| Sanofi-aventis U.S. LLC | 7 | $168 |
| Lilly USA, LLC | 8 | $151 |
| Sanofi | 6 | $136 |
| E.r. Squibb & Sons, L.L.C. | 6 | $116 |
| Boehringer Ingelheim | 5 | $102 |
| ANI Pharmaceuticals, Inc. | 4 | $102 |
| Ferring Pharmaceuticals Inc. | 3 | $77 |
| Mallinckrodt Hospital Products Inc. | 2 | $69 |
| Novartis | 3 | $63 |
| Celltrion USA Inc. | 2 | $56 |
| Sobi, Inc | 3 | $54 |
| Aurinia Pharma U.S., Inc. | 2 | $45 |
| Pacira Therapeutics, Inc. | 1 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| US Oncology Corporate, Inc. | 1 | $19 |
| Janssen Scientific Affairs, LLC | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Bristol Myers Squibb | 1 | $17 |
| Hospira, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
| Sandoz | 1 | $13 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
How this compares
$5,462 in reported general payments places this provider in the 80th percentile of 120 rheumatology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Glendale
- Kurt OelkeGlendale$1.8M
- John AlbertGlendale$369K
- Arnold LimGlendale$8K
- Katherine FinnGlendale$2K
- Farrukh PashaGlendale$1K
- Steven BergquistGlendale$722
- Juliana ShahGlendale$513
- Daniel MaloneBeaver Dam$505K
- Ekaterina SoforoSheboygan$464K
- Fardina MalikMadison$446K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.